Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors

• Main Authors: Hark Kyun Kim (Author), Jeong Won Kang (Author), Young‐Whan Park (Author), Jung Young Kim (Author), Minchae Kim (Author), Soo Jin Kim (Author), Se‐mi Kim (Author), Keun Ho Ryu (Author), Seonghae Yoon (Author), Yun Kim (Author), Joo‐Youn Cho (Author), Keun Seok Lee (Author), Tak Yun (Author), Kiwon Kim (Author), Mi Hyang Kwak (Author), Tae‐Sung Kim (Author), Jinsoo Chung (Author), Joong‐Won Park (Author)
• Format: Book
• Published: Wiley, 2020-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract We report a phase I pharmacological study of an oral formulation of CKD‐516, a vascular‐disrupting agent, in patients with refractory solid tumors. Twenty‐seven patients (16 in the dose‐escalation cohort and 11 in the expansion cohort) received a single daily dose (5‐25 mg) of CKD‐516 five...